Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19817054 | 1.00 | GAA (0.40) | GAAACACBEPHX1EPHX2GFER | |
| SCHEMBL28453830 | 0.90 | CCR2 (0.45) | GAAACACBEPHX1GFERACACA | |
| SCHEMBL25272280 | 0.80 | PDCD1 (0.33) | — | |
| SCHEMBL25313956 | 0.79 | CTSL (0.38) | — | |
| SCHEMBL25313958 | 0.79 | CTSL (0.38) | — | |
| SCHEMBL25313954 | 0.79 | CTSL (0.38) | — | |
| SCHEMBL24013940 | 0.78 | — | — | |
| SCHEMBL23667141 | 0.78 | MTNR1A (0.38) | — | |
| SCHEMBL25134498 | 0.78 | CTSL (0.39) | — | |
| SCHEMBL7390291 | 0.77 | DDB1 (0.41) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324800-A1 | SARS-3CL PROTEASE INHIBITORS | Primmune Therapeutics, Inc. | 2022-10-13 | — | — | US | disclosed |
| WO-2022212707-A1 | SARS-3CL PROTEASE INHIBITORS | Primmune Therapeutics, Inc. (US) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324800-A1 | SARS-3CL PROTEASE INHIBITORS | ACE, ACE2, SARS1 | GAA 355/4885ACACB 1392/4885EPHX1 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.